pegylated interferon alpha 2a, ribavirin — Competitive Intelligence Brief

pegylated interferon alpha 2a, ribavirin (pegylated interferon alpha 2a, ribavirin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy. Area: Virology/Infectious Disease.

marketed Antiviral combination therapy Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase Virology/Infectious Disease Small molecule

Target snapshot

pegylated interferon alpha 2a, ribavirin (pegylated interferon alpha 2a, ribavirin) — Kaohsiung Medical University Chung-Ho Memorial Hospital. Pegylated interferon alpha 2a activates innate immune responses against viral infections, while ribavirin inhibits viral RNA synthesis, together providing antiviral activity primarily against hepatitis C virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
pegylated interferon alpha 2a, ribavirin TARGET	pegylated interferon alpha 2a, ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
pegylated IFN alfa-2b plus ribavirin	pegylated IFN alfa-2b plus ribavirin	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); hepatitis C virus RNA-dependent RNA polymerase
Peg-IFN + LD RBV for 16 weeks	Peg-IFN + LD RBV for 16 weeks	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon alpha receptor; HCV RNA polymerase
C: Peg-interferon alpha-2a & Ribavirin	C: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Pegintron + Riba	Pegintron + Riba	Chang Gung Memorial Hospital	marketed	Antiviral combination therapy (interferon + nucleoside analog)	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
B: Peg-interferon alpha-2a & Ribavirin	B: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); Hepatitis C virus RNA-dependent RNA polymerase
Peg-IFN + WB RBV for 16 weeks	Peg-IFN + WB RBV for 16 weeks	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy class)

1. Kaohsiung Medical University Chung-Ho Memorial Hospital · 6 drugs in this class
2. National Taiwan University Hospital · 6 drugs in this class
3. Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
4. Hepatitis Resource Network · 1 drug in this class
5. Hospices Civils de Lyon · 1 drug in this class
6. MTI Medical Private Limited, Pakistan · 1 drug in this class
7. Pacific Health Foundation · 1 drug in this class
8. RedHill Biopharma Limited · 1 drug in this class
9. Sherief Abd-Elsalam · 1 drug in this class
10. The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · 1 drug in this class